Penn Medicine Co-Investment Program

Overview

The Penn Medicine Co-Investment Program is an initiative by the University of Pennsylvania's medical system to co-invest in healthcare and biotechnology ventures. Established in 2018, the program aims to support faculty entrepreneurs by providing early-stage targeted co-investments in areas such as cell therapy, gene therapy, mRNA, lipid nanoparticles, and connected health technologies. This initiative seeks to translate academic research into commercial applications, fostering innovation and economic growth in the Philadelphia region. By partnering with institutional investors, the program assists in the commercialization of technologies emerging from Penn Medicine labs. Since its inception, it has co-invested over $30 million in 13 Penn Medicine spinouts, which have collectively raised over $1.36 billion in capital, created over 350 jobs, and spent over $50 million with local contract research organizations. The program's focus on faculty-driven innovations underscores its commitment to advancing medical research and improving patient care through strategic investments. Through collaborations with entities like the Penn Center for Innovation, the program continues to play a pivotal role in bridging the gap between academic research and real-world healthcare solutions. Its ongoing efforts contribute to the development of new treatments and technologies that address pressing health challenges, reinforcing the University of Pennsylvania's position as a leader in medical innovation and entrepreneurship.

Investment Focus

• Faculty affiliation with the University of Pennsylvania
• Focus on healthcare and biotechnology sectors
• Alignment with Penn Medicine's strategic interests

Portfolio Companies